Page last updated: 2024-11-04

doxylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Doxylamine is an antihistamine with sedative properties. It is a member of the ethanolamine class of antihistamines. Doxylamine is typically used for the treatment of allergies, such as hay fever and urticaria. It is also used as a sleep aid. Doxylamine is available over-the-counter in the United States. Doxylamine is a competitive antagonist of histamine at the H1 receptor. This means that it blocks the action of histamine by binding to the H1 receptor, preventing histamine from binding. This action helps to relieve the symptoms of allergies, such as sneezing, runny nose, and itchy eyes. Doxylamine is also a sedative because it crosses the blood-brain barrier and acts on the central nervous system. It is often used in combination with other medications, such as decongestants, for the treatment of the common cold. Doxylamine is generally safe and well-tolerated. However, it can cause side effects such as drowsiness, dizziness, and dry mouth. It is important to note that doxylamine can interact with other medications, so it is important to talk to your doctor before taking it if you are taking any other medications.'

Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3162
CHEMBL ID1004
CHEBI ID51380
SCHEMBL ID4709
MeSH IDM0006795

Synonyms (120)

Synonym
AC-15949
n,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
doxilamina
CHEBI:51380 ,
doxylaminum
dossilamina
doxilminio
BRD-A44008656-036-05-0
pyridine, 2-[.alpha.-[2-(dimethylamino)ethoxy]-.alpha.-methylbenzyl]-
ethanamine, n,n-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-
DIVK1C_000841
KBIO1_000841
469-21-6
n,n-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine
pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)-
brn 0230379
hsdb 5184
doxylamine [inn:ban]
dossilamina [dcit]
doxylaminum [inn-latin]
doxilminio [inn-spanish]
nci c60684
einecs 207-414-2
ethanamine, n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-
SPECTRUM_001014
BPBIO1_000103
LOPAC0_000348
BSPBIO_000093
PRESTWICK3_000027
SPECTRUM5_000949
BSPBIO_001938
PRESTWICK2_000027
AB00053466
doxylamine
DB00366
2-dimethylaminoethoxyphenylmethyl-2-picoline
2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
n,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
phenyl-2-pyridylmethyl-beta-n,n-dimethylaminoethyl ether
KBIOGR_001135
KBIO2_001494
KBIO3_001158
KBIO2_006630
KBIO2_004062
KBIOSS_001494
NINDS_000841
PRESTWICK0_000027
PRESTWICK1_000027
SPECTRUM3_000409
SPBIO_000130
SPECTRUM4_000528
SPBIO_002014
SPECTRUM2_000115
IDI1_000841
NCGC00089789-05
NCGC00089789-04
NCGC00089789-02
NCGC00021147-08
CHEMBL1004
L001076
D07878
doxylamine (inn)
n,n-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine
STL018676
NCGC00021147-06
NCGC00021147-09
NCGC00021147-05
NCGC00021147-02
NCGC00021147-03
NCGC00021147-04
CCG-204443
AKOS005657227
ec 207-414-2
unii-95qb77jkpl
5-21-03-00508 (beilstein handbook reference)
95qb77jkpl ,
FT-0603401
doxylaminephenyl-d5
dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine
gtpl7171
doxylamine [hsdb]
doxylamine [vandf]
2-(.alpha.(2-(dimethylamino)ethoxy)-.alpha.-methylbenzyl)pyridine
doxylamine [who-dd]
doxylamine [inn]
(+/-)-doxylamine
doxylamine [mi]
pyridine, 2-(.alpha.-(2-(dimethylamino)ethoxy)-.alpha.-methylbenzyl)-
AB00053466-18
SCHEMBL4709
n,n-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine #
2-(.alpha.-(2-(dimethylamino)ethoxy)-.alpha.-methylbenzyl)pyridine
HCFDWZZGGLSKEP-UHFFFAOYSA-N
.alpha.-dimethylaminoethoxyphenylmethyl-2-picoline
phenyl-2-pyridylmethyl-.beta.-n,n-dimethylaminoethyl ether
HMS3604L05
AB00053466_19
AB00053466_20
DTXSID1022970 ,
SBI-0050336.P004
n,n-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethan-1-amine
n,n-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethanamine
NCGC00021147-13
r-doxylamine
Q423390
BCP09058
BRD-A44008656-036-15-9
SDCCGSBI-0050336.P005
NCGC00021147-21
()-doxylamine
Z2242151271
EN300-123421
doxilminio (inn-spanish)
r06aa09
2-(alpha-(2-dimethylaminoethoxy)-alpha-methylbenzyl) pyridine
dtxcid102970
2-(alpha(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
doxylaminum (inn-latin)
n,n-dimethyl-2-
2-dimethylaminoethoxyphenyl-methyl-2-picoline

Research Excerpts

Overview

Doxylamine succinate is a commonly used antihistamine for respiratory allergies including allergic rhinitis as well as for the management of insomnia. It is a first-generation antihistamines similar in structure to diphenhydramine.

ExcerptReferenceRelevance
"Doxylamine succinate is a commonly used antihistamine for respiratory allergies including allergic rhinitis as well as for the management of insomnia."( Doxylamine succinate overdose: Slurred speech and visual hallucination.
Derinöz-Güleryüz, O, 2018
)
2.64
"Doxylamine is a first-generation antihistamine similar in structure to diphenhydramine. "( Retrospective review of unintentional pediatric ingestions of doxylamine.
Cantrell, FL; Clark, AK; McKinley, M; Qozi, M, 2015
)
2.1
"Doxylamine is an antihistamine of the ethanolamine class. "( Suicide through doxylamine poisoning.
Bockholdt, B; Klug, E; Schneider, V, 2001
)
2.1
"Doxylamine succinate is an antihistaminic drugwith additional hypnotic, anticholinergic and local anesthetic effects first described in 1948. "( Acute pancreatitis and acute renal failure complicating doxylamine succinate intoxication.
Lee, ST; Lee, YD, 2002
)
2

Treatment

ExcerptReferenceRelevance
"Doxylamine treatment caused a dose-dependent increase (up to 2.6-fold) in liver microsomal cytochrome P450 in both male and female mice, at both time points."( Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice.
Bookstaff, RC; Minnema, D; Murphy, VA; Parkinson, A; Sanzgiri, U; Skare, JA, 1996
)
1.41

Toxicity

Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women. Use was not associated with an increased rate of any adverse event over placebo.

ExcerptReferenceRelevance
" Pyridoxine is considered safe for use during pregnancy, but its efficacy in treating nausea and vomiting has not been determined."( Safety and efficacy of antiemetics used to treat nausea and vomiting in pregnancy.
Leathem, AM, 1986
)
0.27
" The objective of this study was to determine the incidence of adverse maternal and fetal effects and pregnancy outcome in 225 women taking Diclectin at the recommended (n = 123) or higher than recommended (n = 102) doses."( The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy.
Atanackovic, G; Koren, G; Moretti, ME; Navioz, Y, 2001
)
0.57
" Adverse events were collected through patient diaries, clinical examination and laboratory testing."( Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015
)
0.69
"Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement."( Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015
)
2.13
"Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy."( Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2015
)
2.13

Pharmacokinetics

The data available on the pharmacokinetic profile of doxylamine in humans are limited, notwithstanding that this drug has been marketed in European countries for more than 50 years. Elderly and young women did not differ significantly in peak plasma doxyamine concentration (Cmax) [116 vs 103 micrograms/L]

ExcerptReferenceRelevance
" Two pharmacokinetic experiments were performed in each animal, one on the first day of treatment and one on the last day of treatment."( Pharmacokinetics of doxylamine given as Bendectin in the pregnant monkey and baboon.
Denton, R; Hendrickx, AG; Holder, CL; Prahalada, S; Rowland, JM; Slikker, W; Young, JF, 1989
)
0.6
" Elderly and young women did not differ significantly in peak plasma doxylamine concentration (Cmax) [116 vs 103 micrograms/L], time to Cmax (tmax) [2."( Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women.
Burstein, ES; Friedman, H; Greenblatt, DJ; Harmatz, JS; Ochs, HR; Scavone, JM; Shader, RI, 1989
)
0.8
"The pharmacokinetic profile of Diclectin well explains its documented delayed efficacy."( Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
Koren, G; Nulman, I, 2009
)
0.59
" For the purpose of this study, pharmacokinetic values for DOX and PLP were adjusted for body weight."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.62
" The method has high sensitivity, specificity and allows high throughput analysis required for a pharmacokinetic study."( Simultaneous determination of dextromethorphan, dextrorphan and doxylamine in human plasma by HPLC coupled to electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.
De Nucci, G; Donato, JL; Koizumi, F; Mendes, GD; Pereira, AS, 2012
)
0.62
" The data available on the pharmacokinetic profile of doxylamine in humans are limited, notwithstanding that this drug has been marketed in European countries for more than 50 years."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.89
"The objective of this study was to evaluate the pharmacokinetic parameters of doxylamine following a single oral dose of doxylamine hydrogen succinate 25 mg in healthy human subjects under fed and fasting conditions."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.87
" Pharmacokinetic parameters were calculated using noncompartmental analysis."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.65
" No statistically significant between-treatment differences were observed for any of the pharmacokinetic parameters under study."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
0.65
" Pharmacokinetic parameters were calculated using non-compartmental analysis."( Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteers.
Cabot, A; Cebrecos, J; Encabo, M; Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Videla, S; Wagner, F; Xu, Z, 2013
)
0.62
"5 mg: mean Cmax 61."( Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteers.
Cabot, A; Cebrecos, J; Encabo, M; Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Videla, S; Wagner, F; Xu, Z, 2013
)
0.62
" Pharmacokinetic parameters were estimated using non-compartmental methods and relationships with age were assessed using linear regression."( Doxylamine pharmacokinetics following single dose oral administration in children ages 2-17 years.
Balan, G; Gibb, R; Hull, D; Li, L; Seeck, M; Thompson, GA, 2013
)
1.83
" Pharmacokinetic parameters were calculated for each study period using standard, non-compartmental methods, and differences were assessed using ANOVA."( Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy.
Gill, SK; Koren, G; Macleod, S; Vranderick, M, 2013
)
0.61

Bioavailability

Intranasal bioavailability was greater than that of oral doxylamine succinate (70 mg tablets) Doxylamine. succinate 25  mg tablets exhibited similar oral bioavailability in the fasting state (mean maximum plasma drug concentration [C(max)] 118.

ExcerptReferenceRelevance
" Intranasal bioavailability was greater than that of oral doxylamine succinate (70."( Comparative pharmacokinetics of single doses of doxylamine succinate following intranasal, oral and intravenous administration in rats.
du Plessis, J; du Preez, JL; Goosen, C; Müller, DG; Pelser, A, 2002
)
0.81
"Diclectin exhibited similar oral bioavailability to those of the oral solutions."( Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrocholoride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age.
Koren, G; Nulman, I, 2009
)
0.59
"To determine the pharmacokinetics of DOX and pyridoxine after oral administration of two tablets of this drug combination in the form of Diclectin and to calculate their respective relative bioavailability by comparison with intravenous administration in another population."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.62
" Based on literature values of the PLP-AUC0→∞ after intravenous administration and data from the current study, the relative bioavailability of pyridoxine in Diclectin was calculated at 100%."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.62
" Using literature values and data from the current study, we estimated the oral bioavailability of pyridoxine to be 100%."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.62
" Doxylamine succinate 25 mg tablets exhibited similar oral bioavailability of doxylamine in the fasting state (mean maximum plasma drug concentration [C(max)] 118."( Food effects on the pharmacokinetics of doxylamine hydrogen succinate 25 mg film-coated tablets: a single-dose, randomized, two-period crossover study in healthy volunteers.
Encina, G; Guibord, P; Lahjou, M; Sans, A; Sicard, E; Tolrà, C; Videla, S; Xu, Z, 2012
)
1.56

Dosage Studied

Three glucuronide metabolites of doxylamine succinate were collected in a single fraction using high-performance liquid chromatography (HPLC) from the urine of dosed male Fischer 344 rats. All developed methods can be successfully applied for simultaneous spectrophotometric determination of doXYlamine and pyridoxine both in laboratory-prepared mixtures and commercial dosage forms.

ExcerptRelevanceReference
" A control of the actual rectal dosage scheme for repetitive applications is recommended and the combination of paracetamol with sedatives is to be discussed."( [On the antipyretic effect of paracetamol. Clinical investigation with two different forms of application (author's transl)].
Götte, R; Liedtke, R, 1978
)
0.26
" Bendectin was administered daily, po, at a dosage approximately 10 times the maximum human therapeutic dosage (7 mg/kg/day) throughout organogenesis (approximately days 22 through 50 of gestation) to three cynomolgus monkeys, four rhesus monkeys, and five baboons."( Pharmacokinetics of doxylamine given as Bendectin in the pregnant monkey and baboon.
Denton, R; Hendrickx, AG; Holder, CL; Prahalada, S; Rowland, JM; Slikker, W; Young, JF, 1989
)
0.6
"Three glucuronide metabolites of doxylamine succinate were collected in a single fraction using high-performance liquid chromatography (HPLC) from the urine of dosed male Fischer 344 rats."( Desorption chemical ionization and fast atom bombardment mass spectrometric studies of the glucuronide metabolites of doxylamine.
Gosnell, AB; Holder, CL; Korfmacher, WA; Lay, JO; Miller, DW; Siitonen, P, 1986
)
0.76
"Experiments were conducted with male and female rats (12 per group) dosed by gavage with 2 or 20 mg (based on the free amine) doxylamine succinate containing about 10 microCi 14C-doxylamine succinate to determine distribution and excretion of the activity as a function of dose and sex with time."( Metabolism of doxylamine succinate in Fischer 344 rats. Part I: Distribution and excretion.
Cmarik, JL; Gosnell, AB; Holder, CL; Rowland, KL; Siitonen, PH; Thompson, HC,
)
0.7
" There was no correlation between dosage and the number of prenatal deaths."( Evaluation of bendectin embryotoxicity in nonhuman primates: II. Double-blind study in term cynomolgus monkeys.
Booher, S; Cukierski, M; Hendrickx, AG; Janos, G; Nyland, T; Prahalada, S, 1985
)
0.27
" No dose-response relationship was evident."( Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy.
Birch, JM; Cartwright, RA; Hartley, AL; Hopton, PA; Johnston, HE; Mann, JR; McKinney, PA; Stiller, CA; Waterhouse, JA, 1985
)
0.27
" Analytical chemical procedures that ensure proper concentration, homogeneity, and stability of the drug in dosed feed, as well as the safety of personnel and the environment, were prerequisites for the toxicological tests."( Trace analysis of doxylamine succinate in animal feed, human, urine, and wastewater by GC using a rubidium-sensitized nitrogen detector.
Bowman, MC; Holder, CL; Thompson, HC, 1982
)
0.6
" It consists of a five-part analysis of epidemiologic studies, secular trend analysis, animal studies, dose-response relationships, and biologic plausibility."( Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen.
Brent, RL,
)
0.13
" Statistics for dose-response trend tests are calculated within body weight strata and pooled to obtain an overall dose-response trend test."( Dose-response trend tests for tumorigenesis, adjusted for body weight.
Gaylor, DW; Kodell, RL, 1999
)
0.3
" Women should receive a dosage according to their body weight and severity of their symptoms."( Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing.
Boskovic, R; Einarson, A; Koren, G; Maltepe, C; Wolpin, J, 2003
)
0.32
" These methods could be applied to determine DOX, PYR, and FA in their combined dosage forms."( Simultaneous determination of a ternary mixture of doxylamine succinate, pyridoxine hydrochloride, and folic acid by the ratio spectra-zero-crossing, double divisor-ratio spectra derivative, and column high-performance liquid chromatographic methods.
Pathak, A; Rajput, SJ,
)
0.38
" At the scene were numerous bottles of methadone, with the chronic dosage of 240 mg 3 times a day."( Cause of death conundrum with methadone use: a case report.
Benson, BE; Letsky, MC; Seifert, SA; Zumwalt, RE, 2011
)
0.37
" Therefore, interindividual differences in metabolism, and not in bioavailability, may be important sources of variability that need to be addressed in dosing guidelines."( Systemic bioavailability and pharmacokinetics of the doxylamine-pyridoxine delayed-release combination (Diclectin).
Garcia-Bournissen, F; Gill, SK; Koren, G, 2011
)
0.62
" Since transdermal promethazine does not exist world wide, and, since this medicine has significant added values compared to the oral/rectal dosage forms, compounding pharmacists should offer physicians transdermal promethazine as a second-line therapy in nausea and vomiting in pregnancy."( Nausea and vomiting in pregnancy: a review of the pathology and compounding opportunities.
Zur, E,
)
0.13
" Plasma samples were obtained before and for 72 hours after dosing and analyzed for doxylamine using HPLC MS/MS."( Doxylamine pharmacokinetics following single dose oral administration in children ages 2-17 years.
Balan, G; Gibb, R; Hull, D; Li, L; Seeck, M; Thompson, GA, 2013
)
2.06
" This article reviews the indications, dosage and nursing interventions associated with using doxylamine succinate/pyridoxine to treat NVP."( A new pharmacologic treatment for nausea and vomiting of pregnancy.
Fantasia, HC,
)
0.35
" Study drug dosing occurred for 14 days, which is substantially longer than what has been performed in similar studies."( Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy.
Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2016
)
0.66
"A four day study drug dosing trial with Diclegis® is sufficient to document efficacy, as the results are similar to those achieved after 14 study drug dosing days."( Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy.
Caritis, SN; Clark, S; Hankins, GD; Koren, G; Matok, I; Mattison, DR; Miodovnik, M; Umans, JG, 2016
)
0.66
" Patients were divided into two groups: in first one patients took reslip and in the second one donormyl in same dosage and regimen."( [Effectiveness of reslip (doxylamine) in short-term insomnia: multicenter comparative randomized study].
Bikbulatova, LF; Ivanova, YA; Lavrik, SY; Melnikov, AY; Raginene, IG; Zakharov, AV,
)
0.43
" All developed methods can be successfully applied for simultaneous spectrophotometric determination of doxylamine and pyridoxine both in laboratory-prepared mixtures and commercial dosage forms."( Advanced spectrophotometric chemometric methods for resolving the binary mixture of doxylamine succinate and pyridoxine hydrochloride.
Al-Degs, Y; Alin, A; Gergov, G; Kassarova, M; Katsarov, P; Pilicheva, B; Simeonov, V, 2018
)
0.92
" Despite their advantages as pharmaceutical formulations, one of the major challenges is achieving sustained drug release, which would diminish toxicity and dosage frequency."( Chemical cross-linking: A feasible approach to prolong doxylamine/pyridoxine release from spray-dried chitosan microspheres.
Gergov, G; Kassarova, M; Katsarov, P; Pilicheva, B; Uzunova, Y, 2018
)
0.73
"After intrathecally injecting the rats with five different doses, the dose-response curves of spinal sensory and motor block with doxylamine and triprolidine were constructed."( Spinal sensory and motor blockade by intrathecal doxylamine and triprolidine in rats.
Chen, YW; Chiu, CC; Hung, CH; Tzeng, JI; Wang, JJ, 2018
)
0.94
" There are different pharmaceutical dosage forms in the European market."( Comparative dissolution profiles of two anti-emetic delayed release dosage forms of doxylamine and pyridoxine: Xonvea® tablets vs. Cariban® capsules.
Alcocer, C; Gergic, E; Hoarau, D; Iraola, M; Perez de la Cruz, MA; Regidor, PA; Rom, E, 2022
)
0.95
"The corresponding methods are suitable to determine PYR and DOX in pure form, pharmaceutical dosage form, and in the presence of DOX DEG product."( Chemometric Quality Assessment of Doxylamine Succinate With Its Degradation Product: Implementation of Two Predictive Models on UV-Spectrophotometric Data of Anti-Emetic Binary Mixture.
Abd El-Hadi, HR; Eissa, MS; Eltanany, BM; Zaazaa, HE, 2022
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
histamine antagonistHistamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists.
cholinergic antagonistAny drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists.
sedativeA central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
antiemeticA drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors.
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
anti-allergic agentA drug used to treat allergic reactions.
antitussiveAn agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
tertiary amineA compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Doxylamine H1-Antihistamine Action87

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
arylsulfatase AHomo sapiens (human)Potency30.13131.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.00000.035520.977089.1251AID504332
flap endonuclease 1Homo sapiens (human)Potency0.18890.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (378)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990169 (44.71)18.7374
1990's48 (12.70)18.2507
2000's52 (13.76)29.6817
2010's83 (21.96)24.3611
2020's26 (6.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.82 (24.57)
Research Supply Index6.15 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index201.18 (26.88)
Search Engine Supply Index3.30 (0.95)

This Compound (69.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials48 (11.48%)5.53%
Reviews42 (10.05%)6.00%
Case Studies45 (10.77%)4.05%
Observational1 (0.24%)0.25%
Other282 (67.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Single Site, Open-label, Randomized, Two Treatments, Two Periods, Two Sequences, Crossover Trial to Evaluate the Bioequivalence of Two Delayed-release Oral Formulations of a Fixed Combination of Doxylamine Succinate 10 mg/Pyridoxine Hydrochloride 10 mg (T [NCT03905564]Phase 10 participants (Actual)Interventional2019-06-30Withdrawn(stopped due to Sponsor decision)
Effectiveness of Acupuncture and Doxylamine/Pyridoxine for Moderate to Severe Nausea and Vomiting in Pregnancy: A Randomized Controlled Two-by-two Factorial Trial [NCT04401384]Phase 3352 participants (Actual)Interventional2020-06-21Completed
A Single-dose, Open-label, Multi-center Study Evaluating the Pharmacokinetics of Doxylamine Succinate in Children Ages 2 to < 18 Years [NCT00796315]Phase 141 participants (Actual)Interventional2008-12-31Completed
Open Randomized Cross-over Two-period Study on Comparative Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Enteric-soluble Film-coated Tablets, 10 mg + 10 mg (Valenta Farm, Russia) in Healthy Volunteers in Fasted Conditions [NCT05498233]28 participants (Actual)Interventional2022-08-18Completed
A Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Of The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy [NCT00614445]Phase 3280 participants (Actual)Interventional2008-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00614445 (1) [back to overview]Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).
NCT00796315 (2) [back to overview]AUC of Doxylamine
NCT00796315 (2) [back to overview]Cmax of Doxylamine

Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).

The objective of this double-blind, randomized, placebo-controlled study was to assess the efficacy, safety, and tolerability of oral Diclectin® in the treatment of nausea and vomiting of pregnancy (NVP) as measured by the Pregnancy Unique-Quantification of Emesis (PUQE) overall score of symptoms from baseline (Day 1) to end of study visit (Day 15). The PUQE score measured hours of nausea, number of times vomiting, and number of times retching for a TOTAL overall score of symptoms on a scale rated from 3 (no symptoms) to 15 (most severe). (NCT00614445)
Timeframe: Baseline (Day 1) to End of Study Visit Day 15 (± 1 day)

InterventionPUQE Score (Mean)
Diclectin®-4.8
Placebo-3.9

[back to top]

AUC of Doxylamine

Area under the time-concentration curve for Doxylamine from 0 to 72 hours post-dose plus an extrapolated area from 72 hours to infinity. (NCT00796315)
Timeframe: 72 Hours

Interventionng*h/mL (Geometric Mean)
Subjects Aged 2-5 Years461.9
Subjects Aged 6-11 Years810.1
Subjects Aged 12-17 Years827.0

[back to top]

Cmax of Doxylamine

Maximum concentration of Doxylamine from 0 to 72 hours post-dose (NCT00796315)
Timeframe: 72 Hours

Interventionng/mL (Geometric Mean)
Subjects Aged 2-5 Years50.1
Subjects Aged 6-11 Years65.8
Subjects Aged 12-17 Years63.2

[back to top]